₹ 871.69 Cr
2.3%
BSE Healthcare TRI
INF209KB1N91
1000.0
1000.0
100
Mr. Dhaval Shah
Fund Performance | 1Y (%) | 3Y (%) | 5Y (%) |
---|---|---|---|
Aditya Birla Sun Life Pharma and Healthcare Fund-Regular-Growth | 1.93 | 22.92 | 16.56 |
Benchmark | - | - | - |
Equity
Debt
Others
The scheme provides long term capital appreciation by investing in equity/equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India. The Scheme does not guarantee/indicate any returns. There can be no assurance that the schemes’ objectives will be achieved.
Company | Holdings (%) |
---|---|
SUN PHARMACEUTICAL INDUSTRIES LTD. EQ NEW F.V. RE.1/- | 11.38 |
APOLLO HOSPITALS ENTERPRISE LIMITED EQ NEW F.V. RS.5/- | 7.31 |
CIPLA LIMITED EQ NEW FV RS.2/- | 6.73 |
FORTIS HEALTHCARE LIMITED. EQ | 5.19 |
ABBOTT INDIA LIMITED EQ | 5.1 |
TORRENT PHARMACEUTICALS LIMITED EQ NEW FV RS.5/- | 4.4 |
LUPIN LIMITED EQ NEW F.V. RS.2/- | 4.34 |
AJANTA PHARMA LIMITED EQ NEW FV RS. 2/- | 4.08 |
IPCA LABORATORIES LIMITED EQ NEW FV RE .1/- | 3.72 |
AUROBINDO PHARMA LIMITED EQ NEW F.V. RE.1/- | 3.55 |
Sector | Holdings (%) |
---|---|
Healthcare | 95.64 |
Financial Services | 1.6 |
Chemicals | 0.82 |